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A B S T R A C T
The anatomical and functional dimensions of bone marrow topography have been at the forefront of
modern bone and immunological research for many years and remain a source of complexity and
perplexity due to the multitude of microhabitats within this microenvironment. In fact, research has
uncovered fascinating functional aspects of bone marrow residents, and the bone marrow niche has been
identiﬁed as the foremost reservoir of a variety of cells including hematopoietic, skeletal and endothelial
stem/progenitor cells. The physical interactions of the marrow residents, combined with the release of
cytokines and growth factors, organize well-deﬁned operative compartments, which preserve bone and
immune cell homeostasis. In a simplistic view, both the hematopoietic and bone marrow stromal
(mesenchymal) stem/progenitor cell populations dwell at the interface between the endosteum and the
bone marrow area (endosteal niche) and in the perivascular space (vascular niche). Indeed, the
tantalizing hypothesis of bone marrow regulatory dependency on these niches is supported by current
research insofar as the increase in the number of osteoblasts results in a concomitant increase in the
hematopoietic population, indicating that the osteoblasts and the endosteal niche are key components of
HSC maintenance. On the other hand, impaired function of the vascular niche compromises the
endosteal niche’s ability to support hematopoiesis. These fascinating discoveries indicate that there are
strong ties between bone marrow inhabitants within the conﬁnes of the bone marrow itself. When these
ties fail, niche-niche communication suffers and results in reduced bone formation, enfeebled
hematopoiesis and unrestrained HSC migration through blood circulation. This study focused on the
extraordinary homeostatic equilibrium and function of both bone and immune cells within the spatially
deﬁned microenvironment of bone marrow. But how important is the anatomically outlined scenery in
which the bone marrow entity supports and hosts the hematopoietic elements?
 2014 Elsevier Ltd. All rights reserved.
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The vertebrae, hips, ribs, skull and long bone cavities host a
remarkable multicellular network in terms of complexity, integri-
ty, functionality and dependency: bone marrow. The bone marrow
microenvironment is committed to accommodating the hemato-
poietic and the bone stem/progenitor cells in a symbiotic,
multifaceted setting. The hematopoietic stem cell (HSCs) popula-
tion is a heterogeneous cell assortment including long-term (LT)
and short-term (ST) components [1]. Under normal conditions the
majority of the HSCs within the bone marrow are dormant or* Corresponding author at: Dimitrios Agas School of Biosciences and Veterinary
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1359-6101/ 2014 Elsevier Ltd. All rights reserved.slowly cycling. According to Cheshier et al. [2] 75% of LT self-
renewing HSCs remain in the G0 state. This state maintains HSC
homeostasis through the control of self-renewal, proliferation and
differentiation of the HSCs and progenitors [3]. The HSCs give rise
to lymphoid progenitors, which differentiate to become immune
cells and myeloid progenitors, which mature into osteoclasts,
macrophages, neutrophils, basophils, eosinophils, megakaryo-
cytes, erythrocytes and dendritic cells [4].
The bone marrow stromal microenvironment encompasses
multiple cell types including bone-lining osteoblasts, endothelial
cells, reticular adventitial cells, neuronal and muscle stem cells and
mesenchymal stem and progenitors components. The bone
marrow-derived mesenchymal stem cells (MSCs) consist of a
self-renewing marrow population with multilineage potential,
physically present in concomitance with the HSCs. The MSCs have
recently been portrayed as perivascular cells with well-deﬁned
roles in microvessel wall formations and in the HSC architecturaltness of bone marrow homeostasis. Cytokine Growth Factor Rev
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grade and, although they are not a pluripotent cell population
(their stemness properties are still an open debate, which tip the
balance in favor of a peculiar non stem/progenitor cell behavior),
can provide bone marrow functional cells, including osteoblasts,
chondroblasts, ﬁbroblasts, adipocytes and endothelial cells [4,6].
The far-reaching MSC features are responsible for the assembly
and organization of the hematopoietic, skeletal and perivascular
niches within the marrow cavity, and, thus, MSCs have been
designated as the preeminent niche manufacturers. Schoﬁeld’s
pioneer study [7] gave prominence to the niche concept and
spurred interest in stem cell research and its spatial dimension,
giving rise to fascinating, as well as, in some cases, contradictory
standpoints. The most important result of this prior research is the
structural and functional singularity of the bone marrow niches
and the value of each niche. From this point of view, both MSC and
HSC niches share distinct anatomical districts with signiﬁcant
functional differences and complexities. This scenario involves the
mature lymphoid components, the endosteal cells (including
osteocytes, osteoblasts, osteoclasts and macrophages) and the
sinusoids, which are demarcated by endothelial cells and
adventitial reticular cells (Fig. 1). In an elegant study, Sacchetti
et al. [8] use the CD146 marker, a cell adhesion molecule of the
immunoglobulin superfamily, to distinguish MSCs from the otherFig. 1. Major interactions between the endosteal and the vascular niche. The hematop
mediators with the mesenchymal stem cells and the bone elements sustaining a physio
types are characterized by elective afﬁnities with the skeletal and immune system that p
disruption of these niche liaisons drives to a pathological tableau including inﬂammato
sympathetic nervous system.
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(2015), http://dx.doi.org/10.1016/j.cytogfr.2014.12.004osteogenic and non-osteogenic progenitors. The CD146+ stromal
cells, on the one hand, generate osteoblasts, which prepare the
endosteal niche, and, on the other hand, differentiate into
sinusoidal adventitial reticular cells, giving rise to the sinusoidal
wall structure and organization. Both the endosteal and sinusoidal
regions deﬁne strategic bone marrow areas, which contribute to
HSC homing and maintenance [8,9]. The niche milieu presents two
types of interaction: 1) an adhesive interaction between stem/
mature cells within the niches [10]; 2) indirect interactions
through cytokines/chemokines and other molecular mediators
[reviewed in 11,12]. The interchanges between these mediators/
cell-cell interactions guarantee stem cell activities within the
niches and maintain bone marrow homeostasis. Accordingly, the
bone-lining osteoblasts synthesize a vast number of cytokines,
which can expand the number of LT-HSCs approximately 2–4-fold
and support the hematopoietic stem/progenitor lineage [13,14].
Moreover, an increase in the osteoblast population reﬂects an
increase in LT-HSCs [14] and, correspondingly, osteoblasts
cotransplanted with HSCs considerably improve engraftment. As
indicated by El-Badry et al. [15], the bone progenitor cells or the
osteoblasts may be crucial components of the stromal cell
population and facilitate engraftment of marrow stem cells in
an allogeneic environment. Intriguing studies prove that not only
can HSCs differentiate into MSCs but myeloid cells can also developoietic stem cells and the mature immune cells exchange a wide number of molecular
logical stand within the bone marrow. The niche dimension and the inhabitant cell
ermit a homeostatic regulation into and beyond the bone marrow topography. The
ry bone diseases, hematopoietic defects and systemic disorders. S: sinusoid; SNS:
tness of bone marrow homeostasis. Cytokine Growth Factor Rev
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alters the landscape of how we understand the bone marrow
cavity. From this point onward, the conception of how the niche
microenvironment manipulates the bone marrow dimension has
been at the forefront of innovative research on MSC related
therapies, HSC engraftment techniques and autoimmune disease
treatments.
2. Does bone marrow ontogeny encompass more than one
functional niche?
Over the last decade research has identiﬁed a number of
interactions within the bone marrow and their protagonists,
fueling the investigation of the spatial relations between these
homeostatic components. The anatomically deﬁned areas that
bring into play the MSC and the HSC metabolites have not always
been considered anatomically and functionally interdependent.
Although the endosteum can even be at a 5-cell distance from the
sinusoids [17], these two anatomical compartments have been
considered either as distinct niches with exclusive functions or
subcompartments of a single niche. In this view, Me´ndez-Ferrer
et al. [18] have denoted that within bone marrow there is a
unique niche shaped of heterotypic stem-cell pairs, although
several sets of evidence support the existence of a multi-niche
tableau. In addition, HSCs reside at the endosteal surfaces, which
provide signals for their homing and regeneration (endosteal
niche). Thus, a body of evidence suggests that the trabecular bone
area is the primary site for HSC homing [14]. A paradigm of the
multi-niche concept originates from the fact that the HSCs were
also found close to the walls of sinusoids, the blood vessels of the
bone marrow cavity (vascular niches) [19–21] (Fig. 2A, B). Kiel
et al. [17,22] propose that a minority of HSCs localize near the
endosteal surface (<20%) and a majority of HSCs (>60%) are
conﬁned to the sinusoid. The same authors have also suggested
that HSCs cannot localize to the endosteum without being
perivascular, and potentially inﬂuenced by factors secreted by
endosteal cells [23]. Likewise, it has been shown that the
endosteal niche maintains HSC quiescence [14,24,25] whereas
the vascular niche supports stem/progenitor cell homeostasis
and regulates megakaryopoiesis [26]. The physiological signiﬁ-
cance of these ﬁndings delineate a complex microarchitecture in
bone marrow. The distinct anatomical compartments include the
candidate niches, which act as coordinators of the bone marrow
microenvironment.
2.1. Spindle-shaped N-cadherin+CD45 osteoblastic cells
In point of fact, specialized cell-residents have been identiﬁed
with a niche-related function. A population of osteoblasts adjacent
to the bone surface, called spindle-shaped N-cadherin+CD45
osteoblastic (SNO) cells, coalesce with the bone-lining osteoblasts
to provide the HSCs a niche within the bone marrow. Zhang et al.
[14] show that the SNO cells enrich both the trabecular bone
surface and the endosteal surface of the long bones. SNO cells
support HSCs (in particular by maintaining the LT-HSCs quiescent/
slow cycling status) by virtue of N-cadherin and b-catenin cell–cell
interactions. It has also been suggested that the increased number
of SNO cells points to an increased number of HSCs, and therefore
SNO cells have been identiﬁed as key components of the niche [14].
However, contradictory studies afﬁrm that N-cadherin interac-
tions do not have a fundamental role in HSC maintenance; HSCs
express low levels of N-cadherin and the lack of N-cadherin in
knockout mice does not inﬂuence the ability of HSCs to sustain
either hematopoiesis over time or bone marrow cellularity
[23,27]. Considering the data reviewed above it remains
questionable whether HSC retention, at the endosteum level,Please cite this article in press as: Agas D, et al. The unbearable ligh
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contact with osteoblasts or on indirect interactions between
various bone marrow cell populations. To address this issue, Arai
and Suda [28] pointed to the fact that, since HSCs adjacent to the
osteoblastic niche have greater N-cadherin levels compared to
those situated in the vascular niche [14], the various N-cadherin
expression levels exert a watchdog role on HSC localization
among the niches.
2.2. Thrombopoietin/Mpl interactions
Quiescence of LT-HSCs is a crucial condition that preserves and
protects the stem cell pool whenever it occurs [29]. LT-HSCs
express the thrombopoietin (THPO) receptor, called Mpl, and the
bone lining cells at the endosteum level produce THPO. THPO was
initially acknowledged as a key regulator of megakaryocyte and
platelet metabolism [30]. Further earlier studies, using Thpo/
and Mpl/ mice, showed impaired HSC maintenance and cell
cycle kinetics [31–33]. Later, the THPO/Mpl signalling interaction
was proposed as an important pathway for the maintenance of LT-
HSCs within bone marrow [25,34]. THPO/Mpl interaction mod-
ulates HSC cycle progression and preserves LT-HSCs quiescence
through regulation of cell-cycle mediators such as p57kip2,
p19Ink4d, Myc and various Homebox transcription factors involved
in HSC self-renewal [25,33]. Moreover, THPO induces the expres-
sion of cell adhesion molecules, such as b1-integrin, supporting
the thesis of direct niche-niche interactions [25]. Although
impaired Myc function induces overexpression of integrins and
N-cadherins in HSCs, resulting in a reduced ability to proliferate
and uncontrollable cell adhesion, a THPO/Mpl-induced Myc
decrease induces the regulation of cell adhesion molecules and
HSC anchoring [35]. Keeping in mind that b1-integrin plays a
critical role in the colonization of hematopoietic organs by HSCs
during embryogenesis and postnatal bone marrow hematopoiesis
[36], the functional dimension of the THPO/Mpl signalling
becomes explicable. Insofar as Mpl+ HSCs are localized in the
endosteal area adjacent to the THPO-producing osteoblasts, these
observations clearly indicate the involvement of the endosteum
cells in HSC metabolism.
2.3. Tunica endothelial cell kinase 2 receptor/angiopoietin-1
signalling
Supporting the concept that the endosteal niche orchestrates
bone marrow homeostasis, Arai et al. [24] have demonstrated the
importance of tunica endothelial cell kinase 2 receptor (Tie2)/
angiopoietin-1 (Ang-1) signalling in HSC homeostasis and its critical
role in the self-renewal ability of HSCs. Ang-1 is well known as the
key component of angiogenesis and contributes to the remodelling
of the slow ﬂow sinusoids within the bone marrow [37]. It is also
accepted that Tie2 is expressed on endothelial cells as well as on
HSCs [38,39] and its ligand Ang-1 is produced by CD146+
osteoprogenitors [8] and by osteoblasts [40]. Tie2+ HSCs are
quiescent, exert anti-apoptotic activities and are localized adherent
to the bone-lining osteoblasts. The Tie2/Ang-1 binding supports
tight adhesion of HSCs to the niche through a N-cadherin/b1-
integrin-dependent mechanism, which results in HSC maintenance
and survival [24]. As previously reported regarding THPO/Mpl
signalling, Tie2/Ang-1 interaction facilitates HSC adhesion to the
niche and provides additional support for the importance of HSC-
bone cell communication at the endosteal level. Another study [8]
shows that the endosteal and perivascular niches are functionally
interdependent. Speciﬁcally, via Ang-1 production, CD146+ sub-
endothelial cells and CD146+ stromal cells regulate the vascular
remodelling and the organization of the vascular structure, which
provide molecular and mechanical support for HSC homing [8].tness of bone marrow homeostasis. Cytokine Growth Factor Rev
Fig. 2. Representative images of cortical and trabecular bone and bone marrow areas in mice. (A) Cortical bone and bone marrow stained with toluidine blue. Note the
bone lining cells adjacent to the endosteum (black arrow) surrounded by the hematopoietic cell population. Erythroid elements present small round dense nuclei;
granulocytes are characterized from larger bean-shaped nuclei; megakaryocytes possess multilobulated nuclei (B) Trabecular bone and bone marrow stained with Congo red.
Note the sinusoids (perivascular niche) close to the trabecular endosteum. (C) OsteoMacs immunoﬂuorescence using the F4/80 antibody. The OsteoMacs are localized at the
endosteum and the BMU area of the cortical bone. (D) Trabecular bone and bone marrow stained with toluidine blue. Note the BMU area with the so-called ‘‘howship’s lacuna’’
formation (bigger black arrows) and the osteoclast (smaller black arrow) action within this compartment during the bone remodelling process. (E) Mesenchymal perivascular
cells immunoﬂuorescence using the a-Sma speciﬁc antibody. Note the close proximity of the labeled cells with the sinusoids and the hematopoietic elements (white arrows).
(F) Sinusoid and perivascular area stained with toluidine blue. Note the mesenchymal stromal cells (red arrows) conﬁned with the endothelial cells (black arrow) and the
hematopoietic population (orange arrow) organizing the vascular niche.
CB: cortical bone; TB: trabecular bone; EC: erythroblastic cells, MC: myeloid cells, BLCs: bone lining cells; S: sinusoids; A: adipocytes; HE: hematopoietic elements; M:
megakaryocyte; OC: osteoclast; OM: osteomacs; BM: bone marrow. Slides were imaged using a Zeiss Axioplan ﬂuorescence microscope.
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Discoveries surrounding macrophage functionality within the
bone marrow have attributed different roles to them based on their
spatial localization. Macrophages resident at the bone marrow
stroma are often interrelated with erythroid precursors to support
erythropoiesis [41]. Macrophages situated at the periosteal and
endosteal surfaces, called OsteoMacs, provide bone-forming
signals during bone apposition [42,43] (Fig. 2C). In line with the
above, macrophages express a variety of osteoinductive factors,
including transforming growth factor-b (TGF-b), bone morphoge-
netic protein (BMP)-2 and 1,25-dihydroxyvitamin D3 [44–46];
conversely, osteoblasts sustain macrophage growth and prolifera-
tion through colony-stimulating factor-1 (CSF-1) production [47].Please cite this article in press as: Agas D, et al. The unbearable ligh
(2015), http://dx.doi.org/10.1016/j.cytogfr.2014.12.004Depletion of macrophages in vivo indicates a complete loss of
endosteal OsteoMacs, loss of neighboring osteoblasts, decrease
in osteoblast-produced cytokines including Ang-1, stem cell
factor (SCF; also known as kit-ligand) and chemokine CXC-li-
gand 12 (CXCL12) and induces HSC mobilization [48]. The
conclusions regarding the critical role of this immune compo-
nent in bone physiology and hematopoietic stem cells metabo-
lism reveal a codependence scenario between OsteoMacs and
osteoblasts.
2.5. Chemokine CXC-ligand 12 and CXCL12-abundant reticular cells
Recently, Ding and Morrison [49] suggested that HSCs reside
adjacent to the perivascular niche whereas early lymphoidtness of bone marrow homeostasis. Cytokine Growth Factor Rev
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signiﬁcance of the perivascular region within the bone marrow
indicate that HSCs localize near reticular cells that express high
levels of CXCL12 [9,18,50]. CXCL12 is expressed by perivascular
stromal cells, as well as by endothelial cells and osteoblasts
[50,51]. The binding of CXCL12 to its physiological receptor
CXCR4 provides signals for HSC maintenance and homing, as
well as for B cell, plasmacytoid dendritic cell and natural killer
(NK) cell maturation [50,52–54]. The CXCL12-abundant reticu-
lar (CAR) cells, which are mesenchymal progenitors, have the
capacity to differentiate into osteoblasts and adipocytes, to
participate in the osteogenic process at the endosteum level and
to organize the hematopoietic microenvironment [8,12,55].
Based on their anatomical location, CAR cells orchestrate HSCs,
lymphoid and erythroid progenitor cell metabolism via cyto-
kines production, such as the SCF and the CXCL12, which are
essential for hematopoietic niche maintenance and retention in
the bone marrow. CAR cell ablation reduces the number of HSCs
by about 50% in the marrow and increase splenic HSCs. For this
reason, CAR cells have been characterized as one of the major
niche-signal providers involved in HSC and hematopoietic
progenitor homeostasis [55]. An interesting approach from
Omatsu et al. [55] suggests that CAR cells exert a regulatory
activity on HSCs. CAR population can maintain HSCs in an
undifferentiated state or can inhibit the myeloid differentiation
of HSCs. Furthermore, the same authors argue that CAR cells
could produce adipogenic and osteogenic markers such as
PPARg, RUNX2 and Osterix enhancing MSC differentiation. It is
also mentioned that CAR cells and/or osteoblasts regulate
monocyte migration from the bone marrow into the circulation
during an inﬂammatory stimulus [56]. This observation is
consistent with results following the conditional deletion of
Cxcl12 in osteoprogenitors that lead to HSC migration toward
the blood and spleen [55] and inﬂuence the chemotaxis of these
hematopoietic elements.
2.6. Calcium-sensing receptor
Chemotaxis of selective bone marrow populations is con-
trolled by ionic calcium through the calcium-sensing receptor
(CaSR), which is a G-protein-coupled receptor expressed in
osteoblasts but also in hematopoietic cells. Variations in calcium
ion concentration play speciﬁc roles in bone modelling and
remodelling, whereas calcium reaches levels of 40 mM near
active osteoclasts [57]. In vitro ﬁndings have shown that local
calcium concentration regulates cell morphology through cell–
cell or cell–matrix interactions, leading to an augmented Ang-1
and connexin43 expression in osteoblasts [58]. Adams et al. [59]
show that HSCs preferentially localize near cells releasing
extracellular calcium and the CaSRs upholding the HSCs in close
juxtaposition to the endosteal surface and, consequently, to the
regulatory niche-maintaining factors. The inﬂuence of CaSR on HSC
homeostasis is also evident in CaSR knockout mice, which are
characterized by hypercalcaemia, bone marrow hypocellularity,
absence of paratrabecular hematopoietic clusters and engraftment
defects [59]. Indeed, on the one hand, CaSR/ mice exhibit reduced
ability to bind the extracellular matrix molecules expressed from
endosteal cells, such as collagen I [59], and, on the other hand,
calcium/CaSR signalling promotes CXCR4/CXCL12 expression and,
thus, HSC homing and retention [60]. These data identify a molecular
network that exceeds the regulatory microenvironment of the single
niche and uniﬁes the endosteal and perivascular elements within a
unique homeostatic scenario. The calcium ion presence at the
endosteum coupled with the ability of CaSRs, CAR cells and
osteomacs to signal for HSCs adhesion and homing strongly support
this view.Please cite this article in press as: Agas D, et al. The unbearable ligh
(2015), http://dx.doi.org/10.1016/j.cytogfr.2014.12.0042.7. Stem cell factor and matrix metalloproteinases
Research in the ﬁeld has provided additional elements to
support the hypothesis that the perivascular stromal cells and
endothelial cells are two key functional components for the
maintenance of HSCs through SCF production. The SCF, expressed
by bone marrow ﬁbroblast, osteoblasts, Cxcl12-expressing
perivascular stromal cells, endothelial cells and Nestin-expres-
sing mesenchymal stem cells [18,55,61], has been proposed as an
important mediator for the preservation of HSC dynamics [62]. In
accordance, Heissing et al. [63] have suggested that matrix
metalloproteinase-9 (MMP-9) exerts a fundamental role on SCF
release, and, consequently, SCF production facilitates bone
marrow recovery under myelosuppression or stress conditions
through accelerating hematopoietic reconstruction. Early studies
on matrix metalloproteinases revealed the implication of MMP-9
in cytokine production, which triggers angiogenesis and osteo-
clast recruitment [64–66]. Bone marrow hematopoietic cells and
MSCs express MMP-9 and, noteworthy, in MMP-9/ mice a
severe drop in hematopoietic clusters at the endosteal and
vascular areas has been observed. In addition, exogenous SCF
administration in MMP-9/ animals restores bone marrow
hypocellularity, accelerates stem cell differentiation and he-
matopoietic reconstitution after bone marrow ablation [63].
These considerations underscore the physiological signiﬁcance of
MMP-9-induced release of SCF to support hematopoiesis in a
steady-state scenario or after myelosuppression. The evidence
that cytokines, such as CXCL12, vascular endothelial growth
factor (VEGF) and granulocytes colony stimulating factor (G-CSF),
enhance MMP-9 production [63], provides additional criteria for
deﬁning the niche functions.
2.8. Nestin-expressing MSCs
Nestin is an intermediate ﬁlament protein expressed in
various progenitor cells and endothelial cells [67]. Nestin-
expressing MSCs are a special bone marrow cell population
that can differentiate into mesenchymal lineages contributing
to skeletal remodelling. These cells present a perivascular
distribution adjacent to the bone and neighboring with HSCs
and adrenergic nerve ﬁbers. Indeed Nestin+ cells show a close
physical association with HSCs and express genes that regulate
the hematopoietic progenitor niche such as Cxcl12, c-kit
ligand, angiopoietin-1, interleukin 7, vascular cell adhesion
molecule-1 and osteopontin. Likewise, it has been established
that HSCs rapidly home near Nestin+ cells and the depletion of
these cells results in a reduction of HSCs within the bone
marrow [18].
In conjunction with Nestin+ cell properties, some studies
have shown the critical role of the sympathetic nervous system
in bone marrow stem cell homeostasis. Nestin+ MSCs express
the b3-adrenergic receptor and play an indirect role in
sympathetic nerve regulation of HSC mobility [18]. In fact,
b-adrenergic receptors signal through the sinusoidal osteopro-
genitor cells and inﬂuence HSC egression from the bone marrow
via Cxcl12 suppression [68]. Another approach by Yamazaki
et al. [69] has upheld that nonmyelinating Schwann cells (glial
cells) laying in proximity to blood vessels in the marrow
not only express stem cell niche genes but also regulate the TGF-
b/Smad signal, which is characterized as one of the critical niche
signals involved in HSC homeostasis. The discoveries surround-
ing Nestin+ MSCs and glial cell-functions dictate a coordinated
and balanced regulation of marrow inhabitants, which act in a
controlled spatial manner to ﬁnally preserve HSC maintenance
and MSC homeostasis.tness of bone marrow homeostasis. Cytokine Growth Factor Rev
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It is well documented that MSCs, as well as HSCs, inhabit the
endosteal and central regions of the bone marrow, with singular
proliferative and immunomodulatory activities [70]. MSCs, local-
ized at the sinusoids, have been portrayed as perisinusoidal
stromal cells and attributed with speciﬁc functional roles within
the bone marrow [8,71]. Explicit structural sections provide
regulatory signals to maintain the stem cell pool and the niche
size. Several studies have revealed that the various niches dwell in
two distinct anatomical compartments: the sinusoidal and the
endosteal compartments [21,72,73]. Analogously, skeletal and
hematopoietic progenitors, which allocate at the same microenvi-
ronment within the long bones, are in competition for the marrow
space, and further, the osteolineage cells orchestrate a variety of
stimuli and interactions that control the niche dimensions
[61,14,74,21]. For instance, bone calcium ions, which accumulate
at the endosteum, inﬂuence the HSC niche expansion via calcium
sensing receptors expressed by the hematopoietic progenitor cells
[59]. In addition, the fact that osteopontin, a sialoprotein produced
by osteoblasts, interacts with HSCs, enhances their migration
toward the endosteal district and limits the number of stem cells
[75–77], strongly supports the above niche-dimension hypothesis.
The spatial and temporal relationships between the niches clearly
illustrate the composite regulatory network of bone marrow. Thus,
the bone residents (including HSCs, MSCs and the mature bone and
hematopoietic cells) exchange molecular mediators, which sustain
their homing, self-renewal, proliferation, differentiation and shape
the niche conﬁnes. This niche dualism and competition can also
shift toward a basal or a pathological bone metabolism through the
control of the inﬂammatory signals and the bone remodelling
process.
4. Bone remodelling under bone marrow components
ascendancy
Physiological bone remodelling is the result of the coordinated
efforts of bone-forming cells, the osteoblasts, and the bone-
resorbing cells, the osteoclasts [4]. As mentioned, OsteoMacs have
speciﬁc functions in bone deposition and mineralization and thus
are deﬁned as the third player in bone remodelling [78]. Since the
remodelling process occurs at the trabecular and cortical surfaces
of the bone, a substantial overlap of molecules and regulatory
mechanisms, shared between bone and immune cells, emerges.
The receptor activator of nuclear factor-kappa B (RANK) ligand
(RANKL), a Tumor Necrosis Factor (TNF) superfamily member that
is expressed by osteoblasts, plays a key role in osteoclastogenesis.
The RANKL binding to its RANK receptor at the surface of osteoclast
precursors prompts receptor trimerization and the activation of
signalling cascades which drives osteoclast formation and migra-
tion at distinct areas called basic multicellular units (BMU). Within
the BMU area, the osteoclasts begin resorption of the old or
damaged bone [79]. Following the resorptive phase, the osteo-
blasts recruited to the BMU secrete collagenous and non-
collagenous proteins for extracellular matrix deposition and bone
formation [80] (Fig. 2D).
The osteoclast activity is not only crucial for bone homeostasis
but also extends to the maintenance and mobilization of immature
hematopoietic progenitors. Notably, stem cell anchorage mole-
cules, such as SCF and osteopontin, have lower expression after
RANKL stimulation. Instead, in PTPe-knockout mice, characterized
by defective osteoclast (and macrophage) functions, RANKL had
impaired effects on HSC progenitor mobilization [81]. Mature
osteoclasts also produce interleukin (IL)-8 and the proteolytic
enzyme MMP-9, both factors involved in progenitor bone marrowPlease cite this article in press as: Agas D, et al. The unbearable ligh
(2015), http://dx.doi.org/10.1016/j.cytogfr.2014.12.004cell mobilization [63,82]. In addition, pre-osteoclasts express
CXCR4 that respond to CXCL12 and in turn increase MMP-9
production [83]. Taking into account that osteoclast precursors are
attracted by CXCL12 signals [83], CXCR4 ablation results in
compromised osteoclast recruitment within the BMU area and
reduced bone-resorption and MMP-9 expression. Kollet et al. [81]
propose an archetypal paradigm of the multiple actions of
osteoclasts. Once osteoclasts reach the BMU area, MMP-9 (which
are able to degrade all components of the ECM as the other MMPs
family proteins) and cathepsin K (a type I collagen protease) exert a
bone-resorbing action, and, furthermore, incite CXCL12 degrada-
tion and bone marrow progenitor cell mobilization. Thus,
osteoclasts perform a dual function: degrading the endosteal
niche components and enhancing egression of HSC progenitors to
the circulation due to the disruption of their anchorage potential
[81]. It is noteworthy how osteoclasts, both in undifferentiated and
mature stages, coordinate bone marrow component kinetics, even
though earlier studies identiﬁed the granulocyte colony-stimulat-
ing factor (G-CSF) as the principal stem cell mobilization factor
[84]. On the contrary, it has been proposed that osteoclast-less or
impaired osteoclast functioning does not necessarily prohibit HSC
progenitor mobilization, and the osteoclast-induced HSC-egres-
sion role remains controversial and case speciﬁc [85]. Interesting
speculation by Purton and Scadden [86] suggests that osteoclast-
induced cell mobility results in a bone stroma-surveillance
mechanism which guards against the overpopulation of the bone
marrow area or/and ﬁne tunes the apparatus that coordinate
hematopoiesis. The clinical signiﬁcance of the above ﬁndings is in
line with the development of the transplantation methodologies
based on mobilizing agent treatments.
The physical competitor of RANKL action is a member of the TNF
receptor superfamily, called osteoprotegerin (OPG), which oper-
ates as a decoy receptor for RANKL. As an osteo-anabolic/anti-
RANKL factor, OPG prevents osteoclast activation and controls
bone loss [87–89]. In this context, transgenic and knockout
animals have been employed to interpret the role of the RANKL/
OPG axis. With reference to the Opg gene functions, it has been
reported that Opg deﬁciency results in bone disorders character-
ized by decreased bone density and increased osteoclast activity
due to an overwhelming RANKL function [4], while OPG over-
expression results in severe osteopetrosis in mice [90] caused by
the failure of osteoclast formation via complete RANKL inhibition.
Polymorphisms in the Opg gene in humans are associated with an
increased incidence of fractures due to a lower mineral density
[4,91]. It is also noteworthy that disruption or functional mutations
in Rankl or Rank result in autosomal recessive osteopetrosis both in
mice [92–96] and humans [97,98]. In addition, 15-base pair
tandem duplications in the RANK gene were observed in patients
diagnosed with expansile skeletal hyperphosphatasia [99]. On
the other hand, when RANKL overwhelms the effects of OPG, as
occurs in RANKL transgenic mice [100] and in postmenopausal
osteoporosis [101], the imbalance in bone remodelling results in
bone resorption. As a consequence, the primary mechanism of
osteoclast regulation and bone remodelling has been ascribed to
the RANKL/OPG ratio.
Likewise, the Wnt signalling pathway plays an essential role in
bone formation, and the osteo-anabolic effects of the canonical
Wnt cascade culminates with b-catenin stabilization, nuclear
translocation and gene transcription activation including c-myc
and OPG [102]. It is well known that canonical Wnt signalling
decreases CXCL12 bone marrow concentrations and facilitates
osteoblasts commitment and differentiation with concurrent
RANKL/OPG ratio regulation [103]. Thus, the coordinated action
of CXCL12, RANKL and OPG, in part arranged by the Wnt secreted
proteins, designate the bone remodelling process and the
mobilization of the participants within the BMU areas. Still, thetness of bone marrow homeostasis. Cytokine Growth Factor Rev
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the relevance of CXCR4 in osteoclastogenesis and osteoclast
recruitment for the initiation of bone resorption. Based on these
ﬁndings, CXCL12/CXCR4 signalling in osteoblasts has been recently
portrayed as playing a preeminent role regarding MSCs and
osteoclast precursor pool size and the recruitment of osteoclasts
and osteoblasts in the bone remodelling sites [104]. Indeed, either
suppression of the osteoblast lineage or osteoblast-speciﬁc CXCR4
deletion accounts for deregulated bone marrow CXCL12 expres-
sion and thus impaired bone-remodelling modulation [104,105].
Antithetically, CXCL12 overexpression in the synovial space and
the bone tissue of patients with rheumatoid arthritis (RA)
aggravates bone disruptive episodes through osteoclasts recruited
to the inﬂamed locus [106]. In point of fact, the key role of CXCL12
in bone and cartilage destruction in pathological scenarios such as
osteoporosis, arthritis and metastatic bone cancers is under broad
investigation (reviewed in 107).
The CXCL12 accomplishment in bone marrow physiology and
bone remodelling progression has recently been correlated with a
bioactive sphingolipid metabolite, the sphingosine-1-phosphate
(S1P). S1P is also synthesized by osteoblast and osteoclasts and
both cell types express its receptors, S1P1 and S1P2 [108]. The
balance between CXCL12 in the bone marrow and the S1P in the
circulation has been portrayed as one of the principal coordinators
of stem cell mobilization. Although S1P concentrations are higher
in the blood, bone marrow concentrations generate an operational
plateau that implicates osteoblast and osteoclast motility, survival,
differentiation and adhesion [reviewed in 109]. Simultaneously,
the S1P/CXCL12 molecular interchanges tune the bone remodel-
ling through chemotactic instructions and signalling cascade
activation such as Rac S1P1-induced and the Rho S1P2-induced
mechanisms [110]. On the other hand, S1P overabundance in
synovial ﬂuids, as previously described for the CXCL12, meets the
pathological RA scenery and drives pro-inﬂammatory cytokines/
chemokines production [111].
5. Mature hematopoietic cells coordinate bone marrow
homeostasis
Accumulating evidence suggests that both mediators of the
adaptive immune system, B and T cells, can carry out osteoinduc-
tive or osteodestructive features and preserve bone homeostasis.
In point of fact, these mature hematopoietic cells produce 20%
RANKL in basal conditions, whereas in an inﬂammatory context
(RA or periodontal tissue diseases) the percentage rises to 50% for B
cells and 90% for T cells [112,113]. In accordance thereto, Manabe
et al. [114] report that B cells are a major source of endogenous
RANKL in bone marrow, and B-lymphoid lineage cells, and in
earlier developmental stages, may have the potential to differen-
tiate into osteoclasts once treated with the osteoclastogenic M-CSF
and soluble RANKL in vitro. M-CSF binds to its receptor c-Fms on
the surface of osteoclast precursors and signals similarly to RANKL/
RANK promoting osteoclast survival, activation and differentiation
[115]. Furthermore, it is well established that T cells play a central
role in the mechanism of ovariectomy (ovx)-induced bone loss. The
estrogen deﬁciency induces T-cell tumor necrosis factor (TNF)
expression and, in turn, the induction of osteoclastogenesis [116].
These ﬁndings were further sustained by the fact that ovx fails to
induce catabolic effects in bone in T cell deﬁcient nude mice [116–
118]. It is also remarkable that the dendritic cells may inﬂuence
RANKL production in T cells and augment bone loss within an
inﬂammatory scenario [119,120]. Within a synergistic plateau,
T cells may regulate the B cell-production of various molecules
involved in bone turnover. B cells can enhance or overwhelm
osteoclastogenesis when stimulated by Th2 or Th1 cytokines,
respectively [121]. The anti-inﬂammatory cytokines produced byPlease cite this article in press as: Agas D, et al. The unbearable ligh
(2015), http://dx.doi.org/10.1016/j.cytogfr.2014.12.004Th cells such as interferon (IFN)-a, IFN-b, IFN-g, IL-4, IL-5, IL-10,
IL-12, IL-13 and IL-18, as well as TGF-b and PTH, have been
classiﬁed as RANKL signalling inhibitors [122,123]. Conversely,
IL-1, IL-3, IL-6, IL-7, IL-11, IL-17, as well as prostaglandin (PG) E2
and TNF, have been characterized as pro-inﬂammatory moderators
leading to pathological osteoclastogenesis via RANKL expression
[12,124]. Moreover, several cytokines (i.e. TNF and IL-1) can act
with RANKL within a combined scenario to directly aggravate bone
resorption [125]. Another T-helper cell subset with an osteoclas-
togenic feature is Th17 which produces IL-17, and is involved in
matrix metalloproteinases synthesis and bone matrix degradation
[126]. Recent ﬁndings emphasize the fact that the anti-inﬂamma-
tory Foxp3+ regulatory T cells (Treg) could converse into Th17 cells
in autoimmune arthritis. The Foxp3 expression furnishes the
suppressive ability of the Treg cells. Komatsu et al. [127],
considering the inﬂammatory microenvironment of arthritis, have
observed that CD25loFoxp3+CD4+ T cells downregulate Foxp3
expression and undergo transdifferentiation into Th17 cells. Th17
express high levels of RANKL resulting in osteoclastogenic
induction and enhanced inﬂammation. Treg plasticity is a
considerable illustration of bone marrow component ductility
under pathologic conditions such as in RA. Opposing views have
posited that RANK/RANKL interaction plays a crucial role in
peripheral CD4+CD25+FoxP3+ Treg homeostasis, while RANKL-
stimulated Treg expansion could convoy anti-inﬂammatory
responses [128]. Although several ﬁndings identify T cells as
one of the principal bone marrow regulators in basal or in
pathological conditions, emerging research has highlighted the
combined effort of the T and B cells within bone cavities. In
addition to T-cells, OPG expression has also been detected in B-
lymphocytes, which participate in B cell hematopoiesis and the
maintenance of bone mass. Of interest, mature B cell OPG-
secretion accounts for about 40% of the total OPG production
composing a regulatory homeostatic network between B cells,
MSCs and osteoblasts [reviewed in 129]. Li et al. [130] assert that
under basal conditions B-cell RANKL secretion remains at low
levels. The same authors state that activated T cells and CD40/
CD40L interaction serve as regulatory stimuli in osteoclastogenesis
stimulating B cell-OPG production within a physiological tableau.
Indeed, CD40/CD40L knockout mice have been attributed an
osteoporotic phenotype with a signiﬁcant decrease in bone
marrow OPG levels [131]. Not to mention that in pathological
conditions B-cell derived OPG plays a watchdog role in osteoclast
maturation and prevents bone destruction [130]. This provides a
comprehensive picture of how the coadjuvancy of these two
immune populations coordinates bone marrow components. The
complexity of bone marrow homeostatic steadiness can be
evaluated if we consider the fact that the marrow inhabitants of
the hematopoietic lineage could exert pro- or anti-inﬂammatory
actions based on the clinical milieu. Although activated T cells have
the capacity to secrete osteoclastogenic cytokines, such as RANKL
and TNF [132,133], it has also been asserted that they conjointly
exert anti-osteoclastogenic effects through cytokines secretion
such as IL-4 [133].
Neutrophil granulocytes are also implicated in RANKL produc-
tion and osteoclastogenic activity in inﬂammatory circumstances
[134]. Another protagonist in the bone marrow microenvironment
is megacaryocyte, which has the potential to drive bone formation
or resorption through RANKL or OPG production [135]. The
discrepancies concerning the anabolic or catabolic effects of the
immune cells on bone could be due to the different clinical
conditions and the compromised niche-to-niche communication
within the bone marrow. The impaired cross-talk between the
bone marrow stromal and hematopoietic components results in
pathologic conditions like chronic inﬂammatory diseases, such as
RA [136,137] and chronic arthritis [138], whereas chronic immunetness of bone marrow homeostasis. Cytokine Growth Factor Rev
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[125].
6. Growth factors and hormone accomplishment within bone
marrow
Bone marrow research has brought to the fore the functional
relationship between the niches and the regulatory molecular
network of cytokines, growth hormones and receptors. Modern
developments in understanding the accomplishment of immune
components in bone homeostasis have established that T cells play
a critical role in regulating the bone-remodelling outcomes of PTH,
an important calcium-phosphate modulator. Namely, T cells
respond to intermittent PTH treatment and enhance osteoblast
differentiation through a Wnt10b/Wnt osteoblastogenic related
mechanism [139–141]. The PTH osteogenic activity and its
consequential capacity to expand the bone niche space have also
been correlated with the increase of the HSC pool and HSC
maintenance. In point of fact, PTH-induced speciﬁc mediators on
bone-lining cell and on HSC, such as N-cadherin, Wnt/b-catenin
and Notch/Jagged1, promote LT-HSC engraftment toward the niche
[61,142]. Mendez-Ferrer et al. [18] have associated HSC expansion
after PTH administration with an increment in Nestin+ MSCs,
highlighting the quintessential role of the various bone marrow
components, including the adventitial reticular cells and the
sympathetic neuronal ﬁbers, in HSCs and MSCs homeostasis.
Parallel studies using genetically modiﬁed mice as regards the PTH
receptor (PPR) established that PPR represents a crucial modulator
of the bone marrow ontogeny and, therefore, of the fate of HSCs
and MSCs [74]. Conversely, continuous PTH administration
switches the metabolic scenario toward a catabolic stance. For
instance, T cells mediate PTH-induced bone loss in hyper-
parathyroidism through the CD40L/CD40 signalling network
[143]. Our previous research brought to light the relevance of
PTH on osteoblast metabolism and the close liaison of ﬁbroblast
growth factor-2 (FGF-2) in this process [144]. The effects of FGF-2
on the skeletal and hematopoietic stem cells have been a subject of
controversy. From one point of view, FGF-2 is acknowledged as an
anabolic bone agent that enhances bone formation by stimulating
MSC proliferation and differentiation in a stage-dependent manner
[145,146]. More than that, FGF signalling regulates the hemato-
poietic developmental events during either early or late differen-
tiation phase [147,148]. Recent ﬁndings by Zhao et al. [149] reveal
that FGF receptor-1 (FGFR1)-mediated response supports HSC
proliferation and facilitates HSC egression to the circulation, both
unavoidable conditions for post-injury hematopoietic recovery.
These observations have revealed the concurrence of the FGF
pathway as part of the hematopoietic stress response and have
given prominence to FGFR1 attendance, acting as a moderator of
NF-kB, CXCL12/CXCR4, AKT and MAPK signalling within the bone
marrow. According to a divergent standpoint, FGF-2 abrogates the
hematopoietic activity and induces compensatory extramedullary
hematopoiesis. These adverse FGF-2 effects occur at a molecular
level, due to the disruption on the CXCL12/CXCR4 axis to Ang-1-
decreased and osteopontin-increased expression, contingencies
that result in a restricted stem cell pool and compromised MSC-
supported HSC homing [8,150,151]. Keeping in mind that a high-
level of seric FGF-2 incites anemia, osteomalacia [152], and clonal
myeloid disorders correlated with severe hematopoietic defects
[153], it is reasonable to deduce that the beneﬁts of this growth
factor on HSC and MSC homeostasis depend on intramedullary
FGF-2 production levels and serum concentrations. To circumvent
the deleterious effects of high doses of FGF-2, Meng et al. [151]
have developed an erythroid-speciﬁc promoter of FGF-2, which
controls FGF-2 concentrations in serum and in the marrow cavity,
and, consequently, leads to trabecular bone formation. In ourPlease cite this article in press as: Agas D, et al. The unbearable ligh
(2015), http://dx.doi.org/10.1016/j.cytogfr.2014.12.004previous studies, using gain-of-function and loss-of-function
approaches, we set out the FGF-2 interrelationship on bone
morphogenetic protein (BMP)-2 osteogenic activity and we
underscored the importance of the crosstalk between both factors
in the osteoblast metabolism [154–156]. BMP signalling plays
multiple roles in bone, bone marrow vascularization and MSC
homeostasis [157]. Therefore, BMP receptor type IA (BMPRIA)
mutations generate dissimilar phenomena in function of the area/
niche. Of note, in Bmpr1a mutant mice, there is an abnormal bone
formation and trabecular bone-like area alteration, as well as
increased numbers of SNO cells and LT-HSCs [14]. Recently, a
mouse model with BMP-2 abrogation in early osteoblasts
displayed compromised micro-capillary architecture, decreased
a-smooth muscle actin (a-SMA)+ MSCs (Fig. 2E, F), CD31 and
CD146 cell pool, coupled with decreased Ang-1 production, and
reduced levels in vascular endothelial growth factor A (VegfA)
within the bone marrow [157]. Considering that the VegfA has
been characterized as a signiﬁcant moderator in blood vessel
formation and in osteoblast precursor maturation [158], and that
the a-SMA+ cell lineage has been involved in angiogenesis during
bone formation [159], it is fathomable that the BMP-2 signal
transduction mechanism can provide extra criteria for the above-
mentioned manipulation of the bone marrow microenvironment.
Several studies have explained the spatio-temporal osteogenic
action of BMP-2 and its clear-cut role in MSC differentiation into
osteoblast progenitors. The destiny of preosteoblasts, among other
bone marrow stimuli, is controlled by TGF-b1, a potent regulatory
cytokine produced by multiple cell types [reviewed in 160].
Indeed, TGF-b1 exerts controlling effects on the bone remodelling
process and has both stage-dependent osteoclastogenic activities
(as a result of NF-kB and RANK induction), and osteoprotective
functions regarding the imbalance of the OPG/RANKL axis via OPG
upregulation [161]. TGF-b produced by glial cells also behaves as a
perivascular niche modulator supporting HSC maintenance [69].
The TGF-b response is in accordance with its concentrations levels
within the bone marrow. Low TGF-b levels support Th17
maturation and consequently osteoclastogenesis, while elevated
levels of this factor sustain Treg-induced MSCs-mediated osteo-
blastogenesis [162]. The TGF-b activity presents a molecular
circuit wherein more inﬂuential factors such as FGF-2, PTH and the
prostaglandins (PGs) have been engaged into a synergistic module,
to become part of the canvas of marrow signalling interactions. As
regards the involvement of PGs within the bone marrow, our
research, along with that of others, has shown the involvement of
these lipid mediators in bone cells as well as in skeletal and
hematopoietic progenitors. Particularly, PGE2 and PGF2a exert a
bifold dose/stage-depended action on osteoblast and osteoclast
metabolism in cell and organ cultures [163,164]. The PGF2a
mitogenic and survival effects on osteoblasts were mediated by
FGF-2 [165], underlining the importance of FGF signalling in the
skeletal and, as previously mentioned, on hematopoietic cells.
Concurrently, other ﬁndings have focused attention on the ability
of PGE2 to facilitate either HSC engraftment via CXCR4 upregula-
tion or HSC egression into the circulation and to provide anti-
apoptotic signals on HSCs via surviving production [166]. PGE2 can
also amplify the PTH effects in the marrow cavity with dissimilar
outcomes, based on the clinical proﬁle of the bone and the
hematopoietic components [167]. Thus, based on the above-
described factors, it is explicable that the molecular mechanisms
within the Daedalean bone marrow entity assume distinct bias in
basal or pathological (inﬂammatory) conditions.
7. Complexities and perplexities of bone marrow topography
The ﬁndings that the stromal elements have a direct impact on
HSCs homeostasis have established over the last two decades atness of bone marrow homeostasis. Cytokine Growth Factor Rev
D. Agas et al. / Cytokine & Growth Factor Reviews xxx (2014) xxx–xxx 9
G Model
CGFR-859; No. of Pages 13unique paradigm for the potency of the bone marrow niche. The
various specialized cell clusters are delineated in distinct
structural areas with conspicuous commitments, such as the bone
marrow adaptability to support HSC homing, egression and
cycling, as well as MSC differentiation and engagement to the
endosteal and perivascular area.
The importance of every single component in the bone marrow
ontogeny is conditioned by complexities and perplexities caused
by the considerable interactions amongst the distinct anatomical
compartments within the axial and long bone cavity. These
complexities arise out of the ﬁne-tuned hematopoietic mecha-
nisms that sustain HSCs and blood cell maturation, as well as the
bone marrow microenvironment, which tends to preserve the HSC
pool at the stable number of 1.1  104 cells in all mammalian
systems [168]. Bone formation and humoral immune system
maturation is based on strong ties between the niche components.
For instance, osteoblasts by RANKL and OPG secretion coordinate B
cell development but only in the precise spatial limits of the
‘‘hematopoietic workroom.’’ Outside these ‘‘B cell maturation
borders,’’ RANKL and OPG carry out different functions (i.e.
osteoblastogenic/osteoclastogenic activities) [reviewed in 169].
But how do these molecules respect the topographic limitations
and act in a niche/context speciﬁc way without being dissipated
into other functional compartments with, in some cases, deleteri-
ous consequences? Up to this point, a clear-cut answer has not
been found.
In a thought-provoking study, Bianco [21] has addressed a
captivating question regarding the contribution of the osteoblasts
to HSC homing and maintenance. A perplexity arises out of the fact
that osteoblasts, from the point of view of osteogenic functionality,
have a rigorous spatio-temporal existence and thus a transient life
at the endosteum level. Consequently, since the HSCs allocated at
the endosteal niche have to deal with endosteal behavior, the
whole ‘‘niche’’ dimension tends to depend on the limited life span
of the osteoblasts. Alternatively, the osteoblast inﬂuences on HSCs
homeostasis remain contingent to an extended regulatory
scenario, which involves additional homeostatic players in the
bone marrow, such as the MSCs, initially identiﬁed as stem cells
and thus far considered multirole elements, such as contributors to
the HSC niche physiology [reviewed in 5]. In addition, the
extramedullary engraftment of the HSCs in the absence or
impaired expression of key regulatory factors within the marrow
area, such as the calcium-sensing receptor, resulted in perplexities
regarding the speciﬁed ‘‘niche harbour’’ properties of the bone
marrow. Indeed, Sacchetti et al. [8] have shown how bone marrow
MSCs (perisinusoidal CD146+ cells) can establish an effective
hematopoietic habitat outside the boundaries of the bone marrow.
In line with this, Seraﬁni et al. [170] have shown in a wider scope
that the heterotopic ‘‘ossicles’’ generated by transplantation of
bone marrow-derived MSCs and by non-mineralized cartilage
pellets formed by bone marrow stromal cells have reproduced a
functionally extramedullary HSC niche. Due to the architectural
and operational posture of these heterotopic ‘‘ossicles,’’ it has
become clear that a role of the MSC is to generate hematopoietic
vascularized microenvironments and emulate the skeletal he-
matopoietic niche assembly.
Recently, it has been described another complex scenario,
which bring into question the topographic niche limitations: the
suppression of key factors involved in the endocondral ossiﬁcation
process, including osterix and VEGF, results in compromised niche
formation and HSC retention [171]. Hence, the endocondral
ossiﬁcation mechanisms, which act within a predesignated local
microenvironment, become an additional issue for the consider-
ation of the niche ontogeny.
The above concerns, which are quite crucial for understanding
the bone marrow ontogeny, are particularly important forPlease cite this article in press as: Agas D, et al. The unbearable ligh
(2015), http://dx.doi.org/10.1016/j.cytogfr.2014.12.004determining the MSC magnitude and the HSC demands, in terms
of microenvironmental constructural/homeostatic characteristics.
Although modern ﬁndings have unveiled salient clues for deﬁning
the mosaic of the bone marrow ontongeny, there is still a long way
to go. Undoubtedly, the in vitro approaches do not always meet the
real scale of the bone marrow concern due to the lack of many
signiﬁcant niche regulators, and the in vivo research has to deal
with systemic organism vicissitudes, and, therefore, the improve-
ment of schemes/assays is warranted. Resolving the complexities
and perplexities associated with bones and bone marrow remains
a compelling task for further research to address.
8. Conclusion
The bone marrow reservoir accommodates an extraordinarily
multipart microenvironment that tends to merge the singular
features of the diverse cell populations in a labyrinthine
homeostatic tableau. The progenitor/stem and mature compo-
nents that inhabit the bone marrow cavity deal with a broad range
of intramural and external molecules and preserve the character-
istic plasticity, consistency and functionality of the bone marrow
compartments. This dynamic hematopoietic and mesenchymal
stem cell incubator, enclosed within the axial and long bones, in
physiological conditions, could be identiﬁed as the body’s ground
control, involved, for example, in bone modelling and remodelling,
immune cell egression and maturation and cooling down pro-
inﬂammatory stimuli. The bone marrow regulatory activities go
beyond its topography and meet the needs of other tissues and
organs (i.e. muscles, adipose tissue and kidney) in terms of the
release of cytokines/chemokines, the control of phosphate/calci-
um, the production of growth factors, their distribution through
circulation, etc. It is also a tremendous cell breeding locus, where
the disruption of the functionality of even one of its residents can
lead to local or systemic pathological conditions, such as chronic
inﬂammation, kidney failure, bone diseases and hematopoietic
disorders.
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